Migraine affects approximately 44 million people in the United States and one billion people globally. The personal, professional, and financial costs through lost productivity and quality of life are immense. Despite its prevalence and impact on individuals, families, and society, migraine is under-recognized, underdiagnosed, and undertreated.
Interviews with patients integrated into the educational activities uncovered chronic migraine episodes that sidelined careers,
New agents targeting the calcitonin gene-related peptide (CGRP) pathway have shown great promise and have led to excitement within the migraine community. Our goal for the Migraine Digital Hub is to provide educational activities, clinical information, resources, and assessment for the diagnosis and management of migraine. Our end goal is to improve the lives of individuals with migraine.
Given the recent position statement from the American Headache Society endorsing calcitonin gene-related peptide receptor antagonists (CGRP-RAs) for first-line prevention of migraine, it is crucial for primary care practitioners to ensure all patients have access to the latest, evidence-based treatments. In this activity, expert faculty will address the educational needs of non-migraine specialist healthcare practitioners. We will discuss common challenges faced by the multidisciplinary care team, including shared decision-making practices to determine the best treatment options for patients.
In this activity, expert faculty will guide you through the evaluation of a patient in the ED, followed by discussions on treatment options, referral processes, accurate diagnosis, and subsequent visits with a neurologist. We will address the educational needs of emergency medicine, non-migraine specialist practitioners and discuss common challenges faced by the multidisciplinary care team to determine the best treatment options for patients.
In this CME Outfitters Snack, expert faculty will address the educational needs of non-migraine specialist healthcare practitioners and the common challenges the multidisciplinary care team faces, including shared decision-making practices when determining the best treatment options.
Migraine is the most common neurological disorder, and the second most common cause of disability in the world. Despite the enormous cost it exacts on patients, the healthcare system, and the greater economy, migraine remains largely undertreated or un-treated. Racial disparities in treatment and outcomes also persist. Even though migraine prevalence is very similar among White, Black, and Latino/Hispanic groups, Black and Latino/Hispanic patients are less likely to even receive a migraine diagnosis than their White peers. Even after diagnosis, patients face unmet treatment needs. Common medications used to treat migraine attacks are poorly tolerated, contraindicated, or simply ineffective in some patients. Newer disease-process-specific therapies may offer hope to patients for whom traditional therapies are ineffective, poorly tolerated, or contraindicated.
During this educational presentation, migraine experts will share real-world examples of screening, diagnosis, and implementation of appropriate pharmacotherapy factoring in social determinants of health and patient access to care.